List of Tables
Table 1. Global Anti-VEGT Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
Table 2. Global Anti-VEGT Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
Table 3. Global Anti-VEGT Drugs Market Competitive Situation by Manufacturers in 2024
Table 4. Global Anti-VEGT Drugs Sales (K Units) of Key Manufacturers (2020-2025)
Table 5. Global Anti-VEGT Drugs Sales Market Share by Manufacturers (2020-2025)
Table 6. Global Anti-VEGT Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
Table 7. Global Anti-VEGT Drugs Revenue Share by Manufacturers (2020-2025)
Table 8. Global Market Anti-VEGT Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
Table 9. Global Key Players of Anti-VEGT Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-VEGT Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-VEGT Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Anti-VEGT Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-VEGT Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-VEGT Drugs as of 2024)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 17. Global Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 18. Global Anti-VEGT Drugs Sales Market Share by Region (2020-2025)
Table 19. Global Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 20. Global Anti-VEGT Drugs Sales Market Share by Region (2026-2031)
Table 21. Global Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 22. Global Anti-VEGT Drugs Revenue Market Share by Region (2020-2025)
Table 23. Global Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 24. Global Anti-VEGT Drugs Revenue Market Share by Region (2026-2031)
Table 25. North America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 26. North America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 27. North America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 28. North America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 29. North America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 30. Europe Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. Europe Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 32. Europe Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 33. Europe Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 34. Europe Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 35. Asia Pacific Anti-VEGT Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 36. Asia Pacific Anti-VEGT Drugs Sales by Region (2020-2025) & (K Units)
Table 37. Asia Pacific Anti-VEGT Drugs Sales by Region (2026-2031) & (K Units)
Table 38. Asia Pacific Anti-VEGT Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 39. Asia Pacific Anti-VEGT Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 40. Latin America Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Latin America Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 42. Latin America Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 43. Latin America Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 44. Latin America Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 45. Middle East and Africa Anti-VEGT Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Middle East and Africa Anti-VEGT Drugs Sales by Country (2020-2025) & (K Units)
Table 47. Middle East and Africa Anti-VEGT Drugs Sales by Country (2026-2031) & (K Units)
Table 48. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2020-2025) & (US$ Million)
Table 49. Middle East and Africa Anti-VEGT Drugs Revenue by Country (2026-2031) & (US$ Million)
Table 50. Global Anti-VEGT Drugs Sales (K Units) by Type (2020-2025)
Table 51. Global Anti-VEGT Drugs Sales (K Units) by Type (2026-2031)
Table 52. Global Anti-VEGT Drugs Sales Market Share by Type (2020-2025)
Table 53. Global Anti-VEGT Drugs Sales Market Share by Type (2026-2031)
Table 54. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2020-2025)
Table 55. Global Anti-VEGT Drugs Revenue (US$ Million) by Type (2026-2031)
Table 56. Global Anti-VEGT Drugs Revenue Market Share by Type (2020-2025)
Table 57. Global Anti-VEGT Drugs Revenue Market Share by Type (2026-2031)
Table 58. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2025)
Table 59. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2026-2031)
Table 60. Global Anti-VEGT Drugs Sales (K Units) by Application (2020-2025)
Table 61. Global Anti-VEGT Drugs Sales (K Units) by Application (2026-2031)
Table 62. Global Anti-VEGT Drugs Sales Market Share by Application (2020-2025)
Table 63. Global Anti-VEGT Drugs Sales Market Share by Application (2026-2031)
Table 64. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2020-2025)
Table 65. Global Anti-VEGT Drugs Revenue (US$ Million) by Application (2026-2031)
Table 66. Global Anti-VEGT Drugs Revenue Market Share by Application (2020-2025)
Table 67. Global Anti-VEGT Drugs Revenue Market Share by Application (2026-2031)
Table 68. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2025)
Table 69. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2026-2031)
Table 70. Genentech (Roche) Company Information
Table 71. Genentech (Roche) Description and Business Overview
Table 72. Genentech (Roche) Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 73. Genentech (Roche) Anti-VEGT Drugs Product
Table 74. Genentech (Roche) Recent Developments/Updates
Table 75. Regeneron Pharmaceuticals Company Information
Table 76. Regeneron Pharmaceuticals Description and Business Overview
Table 77. Regeneron Pharmaceuticals Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 78. Regeneron Pharmaceuticals Anti-VEGT Drugs Product
Table 79. Regeneron Pharmaceuticals Recent Developments/Updates
Table 80. Novartis Company Information
Table 81. Novartis Description and Business Overview
Table 82. Novartis Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 83. Novartis Anti-VEGT Drugs Product
Table 84. Novartis Recent Developments/Updates
Table 85. AstraZeneca Company Information
Table 86. AstraZeneca Description and Business Overview
Table 87. AstraZeneca Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. AstraZeneca Anti-VEGT Drugs Product
Table 89. AstraZeneca Recent Developments/Updates
Table 90. Bayer Company Information
Table 91. Bayer Description and Business Overview
Table 92. Bayer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 93. Bayer Anti-VEGT Drugs Product
Table 94. Bayer Recent Developments/Updates
Table 95. Abbott Company Information
Table 96. Abbott Description and Business Overview
Table 97. Abbott Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 98. Abbott Anti-VEGT Drugs Product
Table 99. Abbott Recent Developments/Updates
Table 100. Santen Company Information
Table 101. Santen Description and Business Overview
Table 102. Santen Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 103. Santen Anti-VEGT Drugs Product
Table 104. Santen Recent Developments/Updates
Table 105. Pfizer Company Information
Table 106. Pfizer Description and Business Overview
Table 107. Pfizer Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 108. Pfizer Anti-VEGT Drugs Product
Table 109. Pfizer Recent Developments/Updates
Table 110. Sanofi Company Information
Table 111. Sanofi Description and Business Overview
Table 112. Sanofi Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 113. Sanofi Anti-VEGT Drugs Product
Table 114. Sanofi Recent Developments/Updates
Table 115. Bristol-Myers Squibb Company Information
Table 116. Bristol-Myers Squibb Description and Business Overview
Table 117. Bristol-Myers Squibb Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 118. Bristol-Myers Squibb Anti-VEGT Drugs Product
Table 119. Bristol-Myers Squibb Recent Developments/Updates
Table 120. GlaxoSmithKline Company Information
Table 121. GlaxoSmithKline Description and Business Overview
Table 122. GlaxoSmithKline Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 123. GlaxoSmithKline Anti-VEGT Drugs Product
Table 124. GlaxoSmithKline Recent Developments/Updates
Table 125. Eli Lilly & Company Company Information
Table 126. Eli Lilly & Company Description and Business Overview
Table 127. Eli Lilly & Company Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Eli Lilly & Company Anti-VEGT Drugs Product
Table 129. Eli Lilly & Company Recent Developments/Updates
Table 130. Chugai Pharma Company Information
Table 131. Chugai Pharma Description and Business Overview
Table 132. Chugai Pharma Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 133. Chugai Pharma Anti-VEGT Drugs Product
Table 134. Chugai Pharma Recent Developments/Updates
Table 135. Kanghong Pharmaceutical Company Information
Table 136. Kanghong Pharmaceutical Description and Business Overview
Table 137. Kanghong Pharmaceutical Anti-VEGT Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 138. Kanghong Pharmaceutical Anti-VEGT Drugs Product
Table 139. Kanghong Pharmaceutical Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. Anti-VEGT Drugs Distributors List
Table 143. Anti-VEGT Drugs Customers List
Table 144. Anti-VEGT Drugs Market Trends
Table 145. Anti-VEGT Drugs Market Drivers
Table 146. Anti-VEGT Drugs Market Challenges
Table 147. Anti-VEGT Drugs Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
Table 151. Authors List of This Report
List of Figures
Figure 1. Product Picture of Anti-VEGT Drugs
Figure 2. Global Anti-VEGT Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Anti-VEGT Drugs Market Share by Type: 2024 & 2031
Figure 4. Tyrosine Kinase Inhibitors Product Picture
Figure 5. Monoclonal Antibodies Product Picture
Figure 6. Others Product Picture
Figure 7. Global Anti-VEGT Drugs Market Value by Application (2020-2031) & (US$ Million)
Figure 8. Global Anti-VEGT Drugs Market Share by Application: 2024 & 2031
Figure 9. Oncology
Figure 10. Ophthalmology
Figure 11. Others
Figure 12. Global Anti-VEGT Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Anti-VEGT Drugs Market Size (2020-2031) & (US$ Million)
Figure 14. Global Anti-VEGT Drugs Sales (2020-2031) & (K Units)
Figure 15. Global Anti-VEGT Drugs Average Price (US$/Unit) & (2020-2031)
Figure 16. Anti-VEGT Drugs Report Years Considered
Figure 17. Anti-VEGT Drugs Sales Share by Manufacturers in 2024
Figure 18. Global Anti-VEGT Drugs Revenue Share by Manufacturers in 2024
Figure 19. Global 5 and 10 Largest Anti-VEGT Drugs Players: Market Share by Revenue in Anti-VEGT Drugs in 2024
Figure 20. Anti-VEGT Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 21. Global Anti-VEGT Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Figure 22. North America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 23. North America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 24. United States Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 25. Canada Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 26. Europe Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 27. Europe Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 28. Germany Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 29. France Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 30. U.K. Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 31. Italy Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 32. Russia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 33. Asia Pacific Anti-VEGT Drugs Sales Market Share by Region (2020-2031)
Figure 34. Asia Pacific Anti-VEGT Drugs Revenue Market Share by Region (2020-2031)
Figure 35. China Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 36. Japan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 37. South Korea Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 38. India Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 39. Australia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 40. China Taiwan Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 41. Southeast Asia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 42. Latin America Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 43. Latin America Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 44. Mexico Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 45. Brazil Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 46. Argentina Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 47. Middle East and Africa Anti-VEGT Drugs Sales Market Share by Country (2020-2031)
Figure 48. Middle East and Africa Anti-VEGT Drugs Revenue Market Share by Country (2020-2031)
Figure 49. Turkey Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 50. Saudi Arabia Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 51. UAE Anti-VEGT Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
Figure 52. Global Sales Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 53. Global Revenue Market Share of Anti-VEGT Drugs by Type (2020-2031)
Figure 54. Global Anti-VEGT Drugs Price (US$/Unit) by Type (2020-2031)
Figure 55. Global Sales Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 56. Global Revenue Market Share of Anti-VEGT Drugs by Application (2020-2031)
Figure 57. Global Anti-VEGT Drugs Price (US$/Unit) by Application (2020-2031)
Figure 58. Anti-VEGT Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
